title: Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer.
abstract: We relieved several side effects by modifying chemotherapy and concurrently using biological response modifiers (BRMs) to experimentally and clinically investigate treatment, which can maintain quality of life (QOL) for lung cancer patients including changes in systemic immune capacity. sIL-2R levels are useful for predicting the course after recurrence. Immunosuppressive acid protein (IAP) levels are useful for detecting the presence or absence of recurrence and for predicting prognosis. BRMs are useful for continuing modified PVP (CDDP + VP-16) therapy, and sIL-2R and IAP levels for clarifying host conditions.
authors.affiliation: First Department of Surgery, Gunma University, School of Medicine, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Katoh
authors.forename: S
authors.initials: S
authors.lastname: Takenoshita
authors.forename: Y
authors.initials: Y
authors.lastname: Shimizu
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Yajima
authors.forename: Y
authors.initials: Y
authors.lastname: Nagamachi
mesh_terms: D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D016190:Carboplatin / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D009367:Neoplasm Staging; D011379:Prognosis; D011509:Proteoglycans / Q000627:therapeutic use*; D011788:Quality of Life; D015375:Receptors, Interleukin-2 / Q000097:blood; D013997:Time Factors; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D009363:Neoplasm Proteins; D011509:Proteoglycans; D015375:Receptors, Interleukin-2; C030193:immunosuppressive acidic protein; C010770:polysaccharide-K; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin